Consequently, Mn-CuS@BSA-FA emerges as a NIR-responsive glycolytic inhibitor, with potential applications in cancer therapy, due to its ability to suppress cellular ATP levels, LDHA activity, and HIF-1α expression. Here, HIF1A is linked to cancer.